Search Our Site

News tagged with:

"ms"

Stem Cell Treatment Could Be a Game-Changer for People With MS

Researchers reported encouraging results for a stem cell transplant for multiple sclerosis (MS) that some doctors and patients hope will be a breakthrough for MS treatment. In a presentation at the European Society for Bone and Marrow Transplantation held in Lisbon, Portugal, scientists said that people with certain forms of MS showed fewer relapses after... Read More »

Read More →

Researchers reported encouraging results for a stem cell transplant for multiple sclerosis (MS) that some doctors and patients hope will be a breakthrough for MS treatment. In a presentation at the European Society for Bone and Marrow Transplantation held in Lisbon, Portugal, scientists said that people with certain forms of MS showed fewer relapses after… Read More »

[...]

Read More

Experts excited by brain ‘wonder-drug’

Scientists hope they have found a drug to stop all neurodegenerative brain diseases, including dementia. In 2013, a UK Medical Research Council team stopped brain cells dying in an animal for the first time, creating headline news around the world. But the compound used was unsuitable for people, as it caused organ damage. Now two... Read More »

Read More →

Scientists hope they have found a drug to stop all neurodegenerative brain diseases, including dementia. In 2013, a UK Medical Research Council team stopped brain cells dying in an animal for the first time, creating headline news around the world. But the compound used was unsuitable for people, as it caused organ damage. Now two… Read More »

[...]

Read More

Novartis’ Gilenya patent loss sets MS market up for battle with early generics

Novartis’ bid to fend off early Gilenya generics has failed in court. The Swiss drugmaker, attempting to salvage a 2026 patent, lost that fight at the U.S. Federal Circuit, leaving the multiple sclerosis blockbuster shielded from generics only through 2019. The decision (PDF) sets up an impending generic rush that stands to not only erode Gilenya’s sales... Read More »

Read More →

Novartis’ bid to fend off early Gilenya generics has failed in court. The Swiss drugmaker, attempting to salvage a 2026 patent, lost that fight at the U.S. Federal Circuit, leaving the multiple sclerosis blockbuster shielded from generics only through 2019. The decision (PDF) sets up an impending generic rush that stands to not only erode Gilenya’s sales… Read More »

[...]

Read More

Stem cell transplant shows promise for MS outcomes

Nearly half of a group of people with multiple sclerosis who were treated with autologous haematopoietic stem cell transplantation (AHSCT) survived for at least five years following the transplant without disease progression, UK-led research has found. Authors of the large observational study,* published online in JAMA Neurology, have now called for full randomised controlled trials... Read More »

Read More →

Nearly half of a group of people with multiple sclerosis who were treated with autologous haematopoietic stem cell transplantation (AHSCT) survived for at least five years following the transplant without disease progression, UK-led research has found. Authors of the large observational study,* published online in JAMA Neurology, have now called for full randomised controlled trials… Read More »

[...]

Read More

New MS Drug Shows ‘Breakthrough’ Promise for Advanced Disease

THURSDAY, Dec. 22, 2016 (HealthDay News) — A new drug slows the progress of multiple sclerosis, including an advanced form of the degenerative nerve disease for which there currently is no treatment, according to a pair of new clinical trials. One MS specialist called the intravenous drug, ocrelizumab, a “breakthrough.” Ocrelizumab reduced the advance of... Read More »

Read More →

THURSDAY, Dec. 22, 2016 (HealthDay News) — A new drug slows the progress of multiple sclerosis, including an advanced form of the degenerative nerve disease for which there currently is no treatment, according to a pair of new clinical trials. One MS specialist called the intravenous drug, ocrelizumab, a “breakthrough.” Ocrelizumab reduced the advance of… Read More »

[...]

Read More

Powerful MS Drug Used Early May Reverse Some Disability

A multiple sclerosis drug usually reserved for people in the late stages of the disease seems to offer long-term remission in newly diagnosed patients, researchers report. Because of serious side effects, the drug — Lemtrada (alemtuzumab) — is approved in the United States only for patients who have failed other treatments. But the authors of... Read More »

Read More →

A multiple sclerosis drug usually reserved for people in the late stages of the disease seems to offer long-term remission in newly diagnosed patients, researchers report. Because of serious side effects, the drug — Lemtrada (alemtuzumab) — is approved in the United States only for patients who have failed other treatments. But the authors of… Read More »

[...]

Read More
Categories
Archives